EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials

Francesco Russano, Mattia Sturlese iD, Luigi Dall'Olmo iD, Francesco Callegarin iD, Davide Brugnolo iD, Paolo Del Fiore iD, Vittoria Patti, Arianna Purpura, Stefano Moro iD, Marco Rastrelli, Simone Mocellin iD

International Journal of Molecular Sciences · 22.12.2025 · 27 (1) · 99

DOI: 10.3390/ijms27010099 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.12.2025. Verfasst von Francesco Russano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology (IOV), 35128 Padua, Italy. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health to cover publication costs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Murine Double Minute 2 (MDM2) gene encodes an E3 ubiquitin ligase that negatively regulates the tumor suppressor p53, maintaining low p53 levels through ubiquitination and proteasomal degradation. MDM2 overexpression in various malignancies leads to reduced p53 activity, contributing to tumor initiation and resistance to therapies. As such, MDM2 is a promising target for drug development. Innovative small-molecule inhibitors are being designed to disrupt the MDM2-p53 interaction, thereby restoring p53’s tumor-suppressive functions. This review focuses on clinical trials evaluating MDM2 inhibition for cancer therapy. MDM2 exerts its oncogenic effects primarily through its interaction with p53 but also has p53-independent functions involved in cell cycle progression and DNA repair. Elevated MDM2 expression is associated with poor prognosis across various cancers, including dedifferentiated liposarcoma, breast cancer, and glioblastoma. Targeting MDM2 with inhibitors has shown promising potential in clinical development, aiming to reactivate p53’s functions in tumors with wild-type TP53, improving therapeutic outcomes in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2NeoplasmsAntineoplastic AgentsHumansTumor Suppressor Protein p53AnimalsClinical Trials as TopicMolecular Targeted Therapy

Stichwörter der Autor:innen

MDM2MDM2 inhibitorscancer therapyclinical trialdrug developmentp53

Substanzen

Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Antineoplastic AgentsMDM2 protein, human

Autor:innen und Institutionen

  • Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology (IOV), 35128 Padua, Italy.
  • Molecular Modeling Section, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35131 Padua, Italy.
  • Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, 35128 Padua, Italy.
  • Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

ORCID-Profile: Mattia Sturlese, Luigi Dall'Olmo, Francesco Callegarin, Davide Brugnolo, Paolo Del Fiore, Stefano Moro, Simone Mocellin

Förderung

  • Italian Ministry of Health to cover publication costs

Zitieren

APA

Russano, F., Sturlese, M., Dall'Olmo, L., Callegarin, F., Brugnolo, D., Del Fiore, P., Patti, V., Purpura, A., Moro, S., Rastrelli, M., & Mocellin, S. (2025). MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials. International Journal of Molecular Sciences, 27(1), 99. https://doi.org/10.3390/ijms27010099

Vancouver

Russano F, Sturlese M, Dall'Olmo L, Callegarin F, Brugnolo D, Del Fiore P, et al. MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials. International Journal of Molecular Sciences. 2025;27(1):99. doi:10.3390/ijms27010099

BibTeX
@article{Russano2025,
  author = {Russano, Francesco and Sturlese, Mattia and Dall'Olmo, Luigi and Callegarin, Francesco and Brugnolo, Davide and Del Fiore, Paolo and Patti, Vittoria and Purpura, Arianna and Moro, Stefano and Rastrelli, Marco and Mocellin, Simone},
  title = {MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {27},
  number = {1},
  pages = {99},
  doi = {10.3390/ijms27010099}
}
Kostenlos starten →